Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus NAPROXEN SODIUM.
ANAPROX vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID